检索结果-南通市图书馆

通信学报 1998年第4期19卷 30-34页

作者：陆建华姚彦清华大学电子工程系

本文研究高效频谱调制方式ＭＰＳＫ及ＭＱＡＭ在蜂窝移动通信中的应用及其性能。在综合考虑共道干扰，Ｒａｙｌｅｉｇｈ衰落以及高斯噪声等影响因素的基础上，结合分集接收技术，我们给出了ＭＰＳＫ及ＭＱＡＭ应用于蜂窝移动通信时误码... 详细信息

本文研究高效频谱调制方式ＭＰＳＫ及ＭＱＡＭ在蜂窝移动通信中的应用及其性能。在综合考虑共道干扰，Ｒａｙｌｅｉｇｈ衰落以及高斯噪声等影响因素的基础上，结合分集接收技术，我们给出了ＭＰＳＫ及ＭＱＡＭ应用于蜂窝移动通信时误码率计算的通用近似公式。蒙特－卡洛仿真表明文中给出的误码率近似公式能很好地吻合实际系统的仿真结果。

关键词：移动通信调制/解调共道干扰 Rayleigh衰落

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Importance of the Glycated Hemoglobin Assay in Congolese Women with Polycystic Ovary Syndrome: A Case-Control Study in Kinshasa, DR Congo

引用

Open Journal of Obstetrics and Gynecology 2019年第11期9卷 1492-1509页

作者： Daddy Kabamba numbi Dophie Tshibuela Beya Guelord Mukiapini Luzolo Passy Kimena nyota Placide Cyanga ngandu Mamy ngole Zita Gustave Ilunga ntita Donatien Kayembe nzongola-nkasu Jérémie Muwonga Masidi Mireille nganga nkanga justin Mboloko Esimo Arsène Mputu Lobota Jean Bosco Kasiam Onkin Baudouin Buassa-bu-Tsumbu Cathy Ali Risasi Fons Verdonck Bernard Spitz Jean Pierre Elongi Moyene Département de Biologie Médicale Service de Biologie Clinique Cliniques Universitaires de Kinshasa Kinshasa DR Congo Département de Gynécologie-Obstétrique Cliniques Universitaires de Kinshasa Kinshasa DR Congo Département de Médecine Interne Service d’Endocrinologie et Diabétologie Cliniques Universitaires de Kinshasa Kinshasa DR Congo Département de Biologie Clinique Hopital Général de Référence de Kinshasa Kinshasa DR Congo Department of Physiology KU Leuven Leuven Belgium Department of Gynecology-Obstetrics KU Leuven Leuven Belgium Département de Gynécologie-Obstétrique Hopital Général de Référence de Kinshasa Kinshasa DR Congo

Context: Polycystic ovary syndrome (PCOS) is considered a syndrome related to the metabolic syndrome with a high risk for developing diabetes mellitus. The evaluation of the glycated hemoglobin (HbA1c) seems to be an interesting tool to detect states of hyperglycemia that may be associated with this syndrome and to understand her pathophysiology. Aims: The purposes of this study are to determine the profile of HbA1c in Congolese women with PCOS, to determine the frequency of states of hyperglycemia and to assess the impact of this marker on clinical signs on this syndrome. Material and methods: This is a case-control study of 130 Congolese subfertile women;65 with a diagnosis of PCOS and 65 others without PCOS. This is conducted from June 2016 to June 2019 among Congolese women of childbearing age. All these women were recruited at the subfertility outpatient clinic of the University Hospital of UnIKIn as well of the YAnGA medical centers in Kinshasa, Democratic Republic of Congo. Sickle cell disease was excluded as also the cases of anemia. HbA1c was assayed via the immunoturbidimetric method and the results interpreted according to the ADA recommendations with a pathological cut-off point ≥ 6.5%. Results: Mean hemoglobin was 11.6 ± 1.2 g/dl (11.5 ± 1.1 g/dl vs. 11.8 ± 1.4 g/dl, P = 0.568). The proportion of diabetics was 1.6% (1.6% vs. 1.5%, P = 0.74). Higher HbA1c values were noted in the PCOS group compared to the control group (7.3% ± 2.1% vs. 5.6% ± 0.6%, P 0.001). The multivariate analysis showed a strong correlation between elevated HbA1c levels and PCOS (OR 14.79 (CI 5.43 - 40.32), P 0.001). In the PCOS group, higher HbA1c values were significantly correlated with a higher socio-economic status (OR 3.38 (1.67 - 8.47), P = 0.018) and with obesity (OR 3.48 IC (1.31 - 7.13) P = 0.029). A perfect, positive and significant linear correlation was found between HbA1c and fasting blood glucose (r = 0.807). 60% of women in the PCOS group had pathological values of H

关键词： PCOS HbA1c Subfertility Congolese Women

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1

引用

World Journal of Gastroenterology 2016年第12期22卷 3418-3431页

作者： Ira Jacobson Stefan Zeuzem Robert Flisiak Brygida Knysz Stefan Lueth Dorota Zarebska-Michaluk Ewa Janczewska Peter Ferenci Moises Diago Anna Linda Zignego Rifaat Safadi Yaacov Baruch Dzhamal Abdurakhmanov Stephen Shafran Dominique Thabut Rafael Bruck Adrian Gadano Alexander James Thompson justin Kopit Fiona Mc Phee Tracy Michener Eric A Hughes Philip D Yin Stephanie noviello Weill Cornell Medical College New YorkNY 10029United States Icahn School of Medicine at Mount Sinai New YorkNY 10029United States JW Goethe University Hospital 60323 FrankfurtGermany Uniwersytet Medyczny w Bialymstoku 15-089 BialystokPoland EMC and Medical University 50-220 WroclawPoland Universitatsklinikum Hamburg-Eppendorf 20246 HamburgGermany Wojewodzki Szpital Zespolony w Kielcach 25-736 KielcePoland ID Clinic 41-400 MyslowicePoland Medizinische Universitat Wien 1090 ViennaAustria Clinica Quiron 46010 ValenciaSpain Universita degli Studi di Firenze 50121 FlorenceItaly Holy Family Hospital Nazareth 6004Israel Rambam Medical Center Haifa 31096Israel 1st Moscow State Medical University n.A.I.M.Sechenov 119991 MoscowRussia University of Alberta Hospital EdmontonAlberta T6G 2B7Canada Groupe Hospitalier Pitie-Salpetriere 75013 ParisFrance Tel Aviv Sourasky Medical Center and Tel Aviv University Tel Aviv 64239Israel Hospital Italiano de Buenos Aires Buenos Aires C1181ACHArgentina St.Vincents Hospital and the University of Melbourne Melbourne 3065Australia Fiona McPhee Bristol-Myers Squibb Research and DevelopmentWallingfordCT 06492United States Bristol-Myers Squibb Research and Development PrincetonNJ 08450United States

AIM: To evaluate daclatasvir vs telaprevir, each combined with peginterferon alfa-2a/ribavirin(peg IFn/RBV), in treatment-naive hepatitis C virus(HCV) genotype(GT) 1-infected ***: In this phase 3, randomized, open-label, noninferiority study, 602 patients were randomly assigned(2:1) to daclatasvir vs telaprevir, stratified by IL28 B rs12979860 host genotype(CC vs non-CC), cirrhosis status(compensated cirrhosis vs no cirrhosis), and HCV GT1 subtype(GT1a vs GT1b). Patients were selected by study inclusion criteria from a total of 793 enrolled patients. Patients received daclatasvir 60 mg once daily or telaprevir 750 mg 3 times daily plus peg IFn/RBV. Daclatasvir recipients received 24 wk of daclatasvir plus peg IFn/RBV; those without an extended rapid virologic response(e RVR; undetectable HCV-RnA at weeks 4 and 12) received an additional 24 wk of peg IFn/RBV. Telaprevir-treated patients received 12 wk of telaprevir plus peg IFn/RBV followed by 12(with e RVR) or 36(no e RVR) wk of peg IFn/RBV. The primary objective was to compare for noninferiority of sustained virologic response rates at posttreatment week 12(SVR12) in GT1b-infected patients. Key secondary objectives were to demonstrate that the rates of anemia(hemoglobin nd rashrelated events, through week 12, were lower with daclatasvir + peg IFn/RBV than with telaprevir + peg IFn/RBV among GT1b-infected patients. Resistance testing was performed using population-based sequencing of the nS5 A region for all patients at baseline, and for patients with virologic failure or relapse and HCV-RnA ≥ 1000 IU/m L, to investigate any link between nS5 A polymorphisms associated with daclatasvir resistance and virologic outcome. RESULTS: Patient demographics and disease characteristics were generally balanced across treatment arms; however, there was a higher proportion of black/African Americans in the daclatasvir groups(6.0% and 8.2% in the GT1 b and GT1 a groups, respectively) than in the telaprevi

关键词： Direct-acting antiviral Chronic hepatitis C Daclatasvir Genotype 1b nS5A inhibitor Liver disease

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

玻璃体内注射曲安奈德治疗视网膜中央静脉阻塞引起的黄斑水肿

引用

美国医学会眼科杂志（中文版） 2005年第2期17卷 76-81,87页

作者： Michael S. Ip justin L. Gottlieb Alon Kahana Ingrid U. Scott Michael M. Altaweel Barbara A. Blodi Ronald E. Gangnon Carmen A. Puliafito 王建民（译）马景学（校） From the Department of Ophthalmology and Visual Science Deparunent of Biostatitics and Medical Informatics University of Wisconsin Madison and the Bascom Palmer Eye Institute Department of Ophthalmology University of Miami School of Medicine Miami Fla 不详

目的：探讨玻璃体内注射丙酮化曲安奈德用于治疗视网膜中央静脉阻塞（CRVO）引起黄斑水肿的安全性和有效性。方法：在Wisconsin大学和Bascom Palmer眼科研究所．对13例（13只眼）连续的CRVO引起黄斑水肿的患者应用玻璃体内注射丙酮化曲... 详细信息

目的：探讨玻璃体内注射丙酮化曲安奈德用于治疗视网膜中央静脉阻塞（CRVO）引起黄斑水肿的安全性和有效性。方法：在Wisconsin大学和Bascom Palmer眼科研究所．对13例（13只眼）连续的CRVO引起黄斑水肿的患者应用玻璃体内注射丙酮化曲安奈德（4mg）治疗．回顾研究其病历记录。每次玻璃体内注射时应用27G或30G针头通过睫状体平坦部注射。主要结果测量：Snellen视力的变化、黄斑水肿的临床表现、应用光学相干断层扫描仪（OCT）测量中心凹的增厚以及并发症的出现频率。结果：13例患者的平均年龄为67岁（四分位数间距为57—77岁）．注射前症状的平均持续时间为8个月（四分位数间距为4—9个月）。患眼在初诊时的平均视力为20／500．在6个月随诊检查时的平均视力为20／1踟。所有13例患者都完成了6个月的随诊检查。非缺血型CRVO患眼（n=5）的视力有显著的提高．而缺血型CRVO患眼（n=8）没有显著的视力提高。患者没有出现视力下降。初诊时OCT测量的平均中心凹厚度为590μm（视网膜增厚=416μm）。12例患者在1个月随诊检查时OCT测量的平均中心凹厚度为212pm（视网膜增厚=38μm）。13例患者在3个月随诊检查时OCT测量的平均中心凹厚度为193μm（视网膜增厚=19μm）。在3和6个月随诊检查之间．4例患者的黄斑水肿复发．其中3例患者再次接受了曲安奈德的注射。这3例患者中的2例经过再次治疗视力提高。在6个月随诊检查时．13例患者OCT测量的平均中心凹厚度为281μm（视网膜增厚=107μm）。没有发生视网膜脱离或眼内炎等并发症。1例患者出现了眼压的升高．应用2种房水生成抑制剂治疗得以控制。结论：在部分CRVO引起黄斑水肿的患者中．玻璃体内注射曲安奈德可能是一种有效的治疗方法。与缺血型CRVO患者相比．非缺血型CRVO患者可以获得更令人满意的效果。部分患者可能需要重复治疗。在本组患者中未发现严重的并发症。

关键词：视网膜中央静脉阻塞玻璃体内注射黄斑水肿治疗方法曲安奈德 Snellen视力中心凹厚度房水生成抑制剂 CRVO 平均年龄

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

A history of high-power laser research and development in the United Kingdom

引用

High Power Laser Science and Engineering 2021年第2期9卷 41-126页

作者： Colin n.Danson Malcolm White John R.M.Barr Thomas Bett Peter Blyth David Bowley Ceri Brenner Robert J.Collins neal Croxford A.E.Bucker Dangor Laurence Devereux Peter E.Dyer Anthony Dymoke-Bradshaw Christopher B.Edwards Paul Ewart Allister I.Ferguson John M.Girkin Denis R.Hall David C.Hanna Wayne Harris David I.Hillier Christopher J.Hooker Simon M.Hooker nicholas Hopps Janet Hull David Hunt Dino A.Jaroszynski Mark Kempenaars Helmut Kessler Sir Peter L.Knight Steve Knight Adrian Knowles Ciaran L.S.Lewis Ken S.Lipton Abby Littlechild John Littlechild Peter Maggs Graeme P.A.Malcolm OBE Stuart P.D.Mangles William Martin Paul McKenna Richard O.Moore Clive Morrison Zulfikar najmudin David neely Geoff H.C.new Michael J.norman Ted Paine Anthony W.Parker Rory R.Penman Geoff J.Pert Chris Pietraszewski Andrew Randewich nadeem H.Rizvi nigel Seddon MBE Zheng-Ming Sheng David Slater Roland A.Smith Christopher Spindloe Roy Taylor Gary Thomas John W.G.Tisch justin S.Wark Colin Webb S.Mark Wiggins Dave Willford Trevor Winstone AWE Aldermaston ReadingUK Oxford Centre for High Energy Density Science Department of PhysicsClarendon LaboratoryUniversity of OxfordOxfordUK Centre for Intertial Fusion Studies Blackett LaboratoryImperial College LondonLondonUK Formerly of Electrox LetchworthUK Formerly of Central Laser Facility Rutherford LaboratoryDidcotUK Formerly of Ferranti Defence Systems LincolnUK Leonardo EdinburghUK Retired AWEReadingUK Formerly of AWE ReadingUK Formerly of Laser Lines Ltd BanburyUK Formerly of Optilas Ltd Milton KeynesUK Retired Pro-Lite TechnologyCranfieldUK Specialised Imaging Ltd PitstoneUK Central Laser Facility STFC Rutherford Appleton LaboratoryDidcotUK Magna-Power Electronics Ltd ReadingUK DeBe Lasers Needham Laser TechnologiesWhitchurchUK Blackett Laboratory Imperial College LondonLondonUK SPIE Europe CardiffUK Professor Emeritus(Physics) University of HullKingston upon HullUK Kentech Instruments Ltd WallingfordUK Department of Physics Clarendon LaboratoryUniversity of OxfordOxfordUK Professor Emeritus Department of PhysicsUniversity of StrathclydeGlasgowUK Department of Physics Durham UniversityDurhamUK Professor Emeritus(Photonics) Heriot-Watt UniversityEdinburghUK Professor Emeritus University of SouthamptonSouthamptonUK Optical Surfaces Ltd KenleyUK JEH Lasers Ltd RugbyUK Scottish Universities Physics Alliance Department of PhysicsUniversity of StrathclydeGlasgowUK ITER Organization Saint-Paul-lez-DuranceFrance Manx Precision Optics Ltd BallasallaUK Laser Lines Ltd BanburyUK Elliot Scientific Ltd MetroTest Scientific GroupHarpendenUK Centre for Plasma Physics Queen’s University BelfastBelfastUK Retired Founderand former MDRofin-Sinar UK LtdHullUK Heraeus noblelight Ltd CambridgeUK Mirli Books ChelmsfordUK M Squared Lasers Ltd GlasgowUK University of Hertfordshire HatfieldUK E&EO UK Ltd Barton-upon-HumberUK Department of Physics University of YorkYorkUK IC Optical Systems Ltd BeckenhamUK Laser Micromachining Ltd St AsaphUK MBDA UK Ltd Brist

The first demonstration of laser action in ruby was made in 1960 by *** of Hughes Research Laboratories,*** laboratories worldwide began the search for lasers using different materials,operating at different *** the UK,academia,industry and the central laboratories took up the challenge from the earliest days to develop these systems for a broad range of *** historical review looks at the contribution the UK has made to the advancement of the technology,the development of systems and components and their exploitation over the last 60 years.

关键词： high-power lasers history United Kingdom

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

一个基于深度学习的眼病和肺炎两大类疾病的AI诊断系统

引用

科学新闻 2019年第2期 33-33页

作者： Daniel S.Kermany Michael Goldbaum Wenjia Cai Carolina C.S.Valentim Huiying Liang Sally L.Baxter Alex McKeown Ge Yang Xiaokang Wu Fangbing Yan justin Dong Made K.Prasadha Jacqueline Pei Magdalene Y.L.Ting Jie Zhu Christina Li Sierra Hewett Jason Dong Ian Ziyar Alexander Shi Runze Zhang Rui Hou William Shi Xin Fu Yaou Duan Viet A.n. Huu Cindy Wen Edward D. Zhang Charlotte L. Zhang Oulan Li Xiaobo Wang Michael A. Singer Xiaodong Sun Jie Xu Ali Tafreshi M. Anthony Lewis Huimin Xia 张康美国加州大学圣地亚哥分校人类基因组医学研究所

文章简介本研究开发了一个基于深度学习框架能诊断致盲性视网膜疾病的人工智能(AI)诊断工具。而且,该AI诊断工具还可用于诊断小儿肺炎。这是一项将AI应用于医疗领域的重磅研究成果,有望高精确诊断多种可治疗性疾病。在眼科治疗中,视网膜... 详细信息

文章简介本研究开发了一个基于深度学习框架能诊断致盲性视网膜疾病的人工智能(AI)诊断工具。而且,该AI诊断工具还可用于诊断小儿肺炎。这是一项将AI应用于医疗领域的重磅研究成果,有望高精确诊断多种可治疗性疾病。在眼科治疗中,视网膜OCT(光学相干断层扫描)

关键词： AI 深度学习

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：